190 related articles for article (PubMed ID: 28188296)
1. Effect of Garlic, Gingko, and St. John's Wort Extracts on the Pharmacokinetics of Fexofenadine: A Mechanistic Study.
Turkanovic J; Ward MB; Gerber JP; Milne RW
Drug Metab Dispos; 2017 May; 45(5):569-575. PubMed ID: 28188296
[TBL] [Abstract][Full Text] [Related]
2. Effect of St John's wort on the disposition of fexofenadine in the isolated perfused rat liver.
Turkanovic J; Ngo SN; Milne RW
J Pharm Pharmacol; 2009 Aug; 61(8):1037-42. PubMed ID: 19703347
[TBL] [Abstract][Full Text] [Related]
3. Effect of St John's wort on the pharmacokinetics of fexofenadine.
Wang Z; Hamman MA; Huang SM; Lesko LJ; Hall SD
Clin Pharmacol Ther; 2002 Jun; 71(6):414-20. PubMed ID: 12087344
[TBL] [Abstract][Full Text] [Related]
4. St. John's wort extract with a high hyperforin content does not induce P-glycoprotein activity at the human blood-brain barrier.
El Biali M; Wölfl-Duchek M; Jackwerth M; Mairinger S; Weber M; Bamminger K; Poschner S; Rausch I; Schindler N; Lozano IH; Jäger W; Nics L; Tournier N; Hacker M; Zeitlinger M; Bauer M; Langer O
Clin Transl Sci; 2024 May; 17(5):e13804. PubMed ID: 38700454
[TBL] [Abstract][Full Text] [Related]
5. Regional absorption of fexofenadine in rat intestine.
MacLean C; Moenning U; Reichel A; Fricker G
Eur J Pharm Sci; 2010 Dec; 41(5):670-4. PubMed ID: 20869437
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of fexofenadine following LPS administration to rats.
Jaisue S; Gerber JP; Davey AK
Xenobiotica; 2010 Nov; 40(11):743-50. PubMed ID: 20863200
[TBL] [Abstract][Full Text] [Related]
7. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.
Schwarz UI; Hanso H; Oertel R; Miehlke S; Kuhlisch E; Glaeser H; Hitzl M; Dresser GK; Kim RB; Kirch W
Clin Pharmacol Ther; 2007 May; 81(5):669-78. PubMed ID: 17392718
[TBL] [Abstract][Full Text] [Related]
8. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
Dresser GK; Schwarz UI; Wilkinson GR; Kim RB
Clin Pharmacol Ther; 2003 Jan; 73(1):41-50. PubMed ID: 12545142
[TBL] [Abstract][Full Text] [Related]
9. St. John's Wort (Hypericum perforatum) induces overexpression of multidrug resistance protein 2 (MRP2) in rats: a 30-day ingestion study.
Shibayama Y; Ikeda R; Motoya T; Yamada K
Food Chem Toxicol; 2004 Jun; 42(6):995-1002. PubMed ID: 15110109
[TBL] [Abstract][Full Text] [Related]
10. Capsaicin pretreatment enhanced the bioavailability of fexofenadine in rats by P-glycoprotein modulation: in vitro, in situ and in vivo evaluation.
Bedada SK; Appani R; Boga PK
Drug Dev Ind Pharm; 2017 Jun; 43(6):932-938. PubMed ID: 28102715
[TBL] [Abstract][Full Text] [Related]
11. Transporter-mediated intestinal absorption of fexofenadine in rats.
Kikuchi A; Nozawa T; Wakasawa T; Maeda T; Tamai I
Drug Metab Pharmacokinet; 2006 Aug; 21(4):308-14. PubMed ID: 16946558
[TBL] [Abstract][Full Text] [Related]
12. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
[TBL] [Abstract][Full Text] [Related]
13. Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats.
Neerati P; Bedada SK
Pharmacol Rep; 2015 Apr; 67(2):339-44. PubMed ID: 25712660
[TBL] [Abstract][Full Text] [Related]
14. An update on the clinical pharmacokinetics of fexofenadine enantiomers.
Akamine Y; Miura M
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):429-434. PubMed ID: 29635947
[TBL] [Abstract][Full Text] [Related]
15. A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort.
Hu ZP; Yang XX; Chen X; Cao J; Chan E; Duan W; Huang M; Yu XQ; Wen JY; Zhou SF
Curr Drug Metab; 2007 Feb; 8(2):157-71. PubMed ID: 17305494
[TBL] [Abstract][Full Text] [Related]
16. Drug interaction between St John's wort and zolpidem in healthy subjects.
Hojo Y; Echizenya M; Ohkubo T; Shimizu T
J Clin Pharm Ther; 2011 Dec; 36(6):711-5. PubMed ID: 21058968
[TBL] [Abstract][Full Text] [Related]
17. Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers.
Akamine Y; Miura M; Sunagawa S; Kagaya H; Yasui-Furukori N; Uno T
Xenobiotica; 2010 Nov; 40(11):782-9. PubMed ID: 20839930
[TBL] [Abstract][Full Text] [Related]
18. Effects of St. John's wort extract on indinavir pharmacokinetics in rats: differentiation of intestinal and hepatic impacts.
Ho YF; Huang DK; Hsueh WC; Lai MY; Yu HY; Tsai TH
Life Sci; 2009 Aug; 85(7-8):296-302. PubMed ID: 19559714
[TBL] [Abstract][Full Text] [Related]
19. Long-lasting inhibition of the intestinal absorption of fexofenadine by cyclosporin A in rats.
Suzuki K; Shitara Y; Fukuda K; Horie T
J Pharm Sci; 2012 Jul; 101(7):2606-15. PubMed ID: 22538465
[TBL] [Abstract][Full Text] [Related]
20. Paroxetine decreased plasma exposure of glyburide partly via inhibiting intestinal absorption in rats.
Jiang S; Zhao W; Chen Y; Zhong Z; Zhang M; Li F; Xu P; Zhao K; Li Y; Liu L; Liu X
Drug Metab Pharmacokinet; 2015 Jun; 30(3):240-6. PubMed ID: 25890690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
